Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Chul Kim, MD, MPH

Latest:

Dr Kim on the Importance of the FDA Approval of Repotrectinib for ROS1+ NSCLC

Chul Kim, MD, MPH, discusses the impact of optimizing rare targets in lung cancer, highlighting the FDA approval of repotrectinib in ROS1-positive disease.

Chul S. Ha, MD

Latest:

Combined Radiation Therapy and Checkpoint Inhibition in Lymphoma: A Case Report and Brief Review

The emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.

Chung-Han (Joe) Lee, MD

Latest:

Non–Clear Cell RCC: Clinical Rationale Behind Therapy

A brief review of the clinical rationale behind therapeutic regimens used for patients with non-clear cell carcinoma.

Chung-Han (Joe) Lee, MD, PhD

Latest:

Dr. Lee on Second-Line Treatment Options in RCC

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Chung-Han Lee, MD, PhD

Latest:

Dr Lee on Extended Follow-Up With Pembrolizumab and Lenvatinib in Pretreated mRCC

Chung-Han Lee, MD, PhD, discusses the final results of the phase 2 cohort of a phase 1/2 trial evaluating lenvatinib plus pembrolizumab in patients with pretreated metastatic clear cell renal cell carcinoma.

Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center

Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Center

Chunkit Fung, MD, MS

Latest:

Androgen Deprivation Therapy and Cardiovascular Risk in Prostate Cancer

Accumulating evidence suggests that androgen deprivation therapy for prostate cancer increases the risk of cardiovascular morbidity and mortality, though not all studies demonstrate an association

Ciara O'Sullivan, MB, BCh

Latest:

Dr. O'Sullivan on Individualized HER2-Targeted Therapy in HER2+ Breast Cancer

Ciara O'Sullivan, MB, BCh, senior associate consultant, assistant professor of oncology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses how HER2-targeted treatment can be more individualized in the treatment of patients with HER2-positive breast cancer.

C.J. Stimson, MD, JD

Latest:

Wholesale Medicine: The Why and How of Physician Engagement in Healthcare Policy

This article discusses the wholesale side of medicine, exploring the why and how of physician involvement in healthcare policy.